Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Medtronic PLC MDT

Healthcare — Medical Devices
S&P 500 Member Dividend Champion (5y) Cash Flow Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
8.92
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 — — 1 — — — 1 1 — 1
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
118,670.00
Revenue
37,542.00
Net Income
5,269.00
Free Cash Flow
6,132.00
Net Debt
19,334.00
Current Ratio
2.07
Debt/Equity
0.55
P/E ratio
22.58
P/S ratio
3.14
P/B ratio
2.32
Past 5Y EPS Growth
0.37%
This Y EPS Growth
8.07%
Next Y EPS Growth
6.99%
Next 5Y EPS Growth
7.71%
in millions of $

Dividends

Payout Ratio
1.01
Annual Dividend Rate
2.76
Annual Dividend Yield
3.07%
total individual payouts
2029 ‡‡‡‡‡
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 2.86
—
—
—
2025 2.83
—
—
—
—
2024 2.79
—
—
—
—
2023 2.75
—
—
—
—
2022 2.67
—
—
—
—
2021 2.47
—
—
—
—
2020 2.28
—
—
—
—
2019 2.12
—
—
—
—
2018 1.96
—
—
—
—
2017 1.81
—
—
—
—
2016 1.67
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 8,005.00 8,965.00 9,220.00 8,819.00
Receivables 6,128.00 6,515.00 6,643.00 6,357.00
Inventory 5,217.00 5,476.00 5,951.00 6,215.00
Other 2,584.00 2,858.00 2,972.00 2,999.00
21,935.00 23,814.00 24,787.00 24,390.00
2024 2025 2026 Q'26
Payables 2,410.00 2,449.00 2,644.00 2,695.00
ST’ Debt 1,092.00 2,874.00 1,788.00 2,536.00
Other — — — —
10,789.00 12,879.00 11,658.00 11,799.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jul Oct Jan Apr Year
’26 9,756.00 — — —
—
’26 8,578.00 8,961.00 9,017.00 9,808.00
36,364.00
’25 7,915.00 8,403.00 8,292.00 8,927.00
33,537.00
’24 7,702.00 7,984.00 8,089.00 8,589.00
32,364.00
’23 7,371.00 7,585.00 7,727.00 8,544.00
31,227.00
’22 7,987.00 7,847.00 7,763.00 8,089.00
31,686.00
’21 6,507.00 7,647.00 7,775.00 8,188.00
30,117.00
in millions of $

Operating Cash Flow

Jul Oct Jan Apr Year
’26 1,793.00 — — —
—
’26 1,088.00 925.00 2,744.00 2,573.00
7,330.00
’25 986.00 958.00 2,572.00 2,528.00
7,044.00
’24 875.00 661.00 2,474.00 2,777.00
6,787.00
’23 1,083.00 922.00 1,574.00 2,460.00
6,039.00
’22 1,292.00 1,769.00 2,228.00 2,057.00
7,346.00
’21 278.00 1,861.00 2,356.00 1,745.00
6,240.00
in millions of $

Free Cash Flow

Jul Oct Jan Apr Year
’26 1,290.00 — — —
—
’26 584.00 457.00 2,300.00 2,085.00
5,426.00
’25 466.00 554.00 2,096.00 2,069.00
5,185.00
’24 521.00 200.00 2,128.00 2,351.00
5,200.00
’23 657.00 599.00 1,242.00 2,082.00
4,580.00
’22 914.00 1,498.00 1,898.00 1,668.00
5,978.00
’21 (56.00) 1,580.00 1,993.00 1,368.00
4,885.00
in millions of $

EPS

Jul Oct Jan Apr Year
’26 1.14 — — —
—
’26 0.81 1.07 0.89 0.96
3.73
’25 0.80 0.99 1.01 0.82
3.61
’24 0.59 0.68 0.99 0.49
2.76
’23 0.70 0.32 0.92 0.88
2.82
’22 0.56 0.97 1.10 1.10
3.73
’21 0.36 0.36 0.94 1.00
2.66

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 75.77 68.84 75.96 79.55 73.31 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 114.31 92.02 92.68 106.33 105.50 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 95,000 95,000 95,000 95,000 95,000 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.33 0.33 0.34 0.35 0.38 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31,686.00 31,227.00 32,364.00 33,537.00 36,364.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 67.98% 65.67% 65.34% 65.32% 65.02% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,517.00 5,364.00 4,837.00 5,628.00 6,136.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.41% 17.18% 14.95% 16.78% 16.87% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,062.00 3,784.00 3,705.00 4,691.00 4,837.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,707.00 2,697.00 2,647.00 2,861.00 2,958.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.60 23.48 24.38 26.09 28.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.75 2.83 2.77 3.63 3.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.47 4.54 5.11 5.48 5.72 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.02) (1.10) (1.20) (1.45) (1.49) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.45 3.44 3.92 4.03 4.23 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.27 38.85 37.98 37.54 39.06 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,342.40 1,329.80 1,327.70 1,285.60 1,281.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.50 32.04 29.18 23.35 21.65 ‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.37 3.86 3.29 3.25 2.85 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.63 2.33 2.11 2.26 2.07 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.80 4.39 3.82 3.83 3.37 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.43 29.91 23.76 24.79 22.58 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,346.00 6,039.00 6,787.00 7,044.00 7,330.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,368.00) (1,459.00) (1,587.00) (1,859.00) (1,904.00) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,978.00 4,580.00 5,200.00 5,185.00 5,426.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10,665.00 12,624.00 11,146.00 10,935.00 13,129.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24,114.00 24,364.00 25,024.00 28,516.00 27,961.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,541.00 16,405.00 17,019.00 19,551.00 18,741.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52,722.00 51,665.00 50,420.00 48,256.00 50,072.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.48% 4.13% 4.06% 5.13% 5.20% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.43% 5.04% 4.77% 5.49% 5.87% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.66% 7.20% 7.20% 9.45% 9.77% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Medtronic PLC (MDT), a dominant force in medical devices across cardiovascular, diabetes, and surgical innovations, has delivered steady revenue growth from $28.8 billion in 2016 to $32.4 billion in 2024 (1.5% CAGR), bolstered by share buybacks and resilient FCF generation despite margin erosion and pandemic disruptions. Trading at levels implying 14% mean analyst upside (up to 22%), the stock has lagged fundamentals amid volatility, with current multiples like 23x forward P/E and 3.8x EV/Sales signaling undervaluation relative to historical norms and sector peers.

Strong balance sheet fundamentals shine through robust operating cash flows ($6.8-7.0B annually) and ROE averaging 7.9%, supporting 52+ years of dividend increases, though rising debt ($28.5B) and supply chain pressures have weighed on gross margins (down to 65.3%). Insider activity leans cautious with sells outweighing modest buys, yet per-share metrics like FCF ($3.92) and revenue ($24.38) correlate tightly with past price peaks.

Looking ahead, analysts forecast revenue acceleration to $40.1B by 2028 (6.2% CAGR) and EPS to $5.20, driven by demographic tailwinds, pipeline catalysts like Hugo RAS and TAVR expansions, and margin recovery. A quantitative model projects 12-18% annualized returns through 2028, with high-probability compounding for patient investors—explore the full analysis for detailed correlations, Monte Carlo simulations, and risk breakdowns.

Read full commentary →

Medtronic PLC (MDT) Latest News

News by impact score

Fine-tune

19 Sep

4 , 4:11 AM
Medtronic secures FDA clearance for its Hugo robotic surgery system, strengthening the company's push into robotic-assisted procedures. FDA clearance directly advances Medtronic's Hugo platform and competitive stance in surgical robotics.

17 Sep

4 www.fool.com, 3:43 PM
Medtronic's Hugo surgical robot advances in market share, prompting questions on MDT stock purchase viability amid robotics competition. Hugo robot progress signals major product innovation that could shift Medtronic's competitive stance in surgical systems.

4 , 10:34 AM
Medtronic raises its outlook again as demand for heart devices keeps climbing. Repeated outlook raises on climbing heart device demand signal strong growth that can significantly shift performance and sentiment.

3 www.medtechdive.com, 6:43 AM
FDA clears vessel-sealing device for Medtronic’s Hugo robot. FDA clearance enables expanded surgical applications for Medtronic Hugo platform.

16 Sep

4 , 12:28 AM
Medtronic advances AI maternal health efforts via Sonus to reframe its investment narrative and growth outlook. AI maternal health push with Sonus marks strategic expansion likely to shift Medtronic's market trajectory and investor sentiment.

3 , 6:30 AM
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo RAS system. FDA clearance supports commercial rollout of additional instrument for Medtronic's Hugo RAS robotic platform.

15 Sep

4 www.marketbeat.com, 8:02 PM
Medtronic expects AI, ablation technologies and targeted M&A to drive its growth and market performance. AI, ablation and targeted M&A represent major strategic initiatives that can materially shift Medtronic's trajectory and investor sentiment.

14 Sep

4 www.medtechdive.com, 7:33 AM
Medtronic PLC initiates final steps to separate its MiniMed diabetes business unit. Separation of MiniMed division represents major strategic restructuring with potential to significantly alter Medtronic's business focus and investor perceptions.

4 , 7:30 AM
Medtronic launches an exchange offer to complete the separation of MiniMed Group, Inc. as a standalone entity. Exchange offer advances full separation of MiniMed diabetes business, enabling strategic refocus and potential value creation for Medtronic.

3 , 10:38 AM
Boston Scientific is relying on acquisitions to support its long-term growth strategy in medical devices, posing competitive pressure on rivals including Medtronic. Competitor acquisition activity can moderately shift market positioning and innovation pace for Medtronic without immediate fundamental change.

3 , 7:30 AM
MiniMed filed a Form S-4 Registration Statement to support Medtronic's exchange offer. S-4 filing advances an exchange offer that may alter Medtronic's corporate structure and shareholder base.

11 Sep

4 www.medtechdive.com, 8:14 AM
CMS expands Medicare coverage for TAVR to asymptomatic patients, increasing eligible cases for the procedure. Broader Medicare eligibility directly enlarges the TAVR patient pool and supports higher procedure volumes for Medtronic.

10 Sep

3 , 10:11 PM
Medtronic's MiniMed unit reports rising patient adoption of its updated insulin pump lineup, strengthening the company's diabetes business amid competitive market conditions. Gaining patients for new pumps supports Medtronic diabetes segment growth without indicating major strategic or financial shifts.

3 , 9:07 AM
Jim Cramer labels Medtronic a quandary as growth surges while diabetes exit approaches. Growth surge paired with diabetes exit signals strategic shift with moderate effect on operations and sentiment.

9 Sep

4 , 10:18 PM
Medtronic's heart devices segment is growing faster than the rest of med-tech, driving stronger overall performance. Faster heart device growth directly lifts Medtronic revenue trajectory and investor sentiment.

4 , 9:12 AM
Medtronic PLC raised its 2027 outlook citing accelerating broad-based growth momentum across operations. Raised 2027 outlook signals major positive momentum likely to lift financial trajectory and investor sentiment.

3 , 7:18 PM
Medtronic raised its financial outlook after heart device sales accelerated, though doubts remain over whether the growth momentum will continue. Outlook increase tied to core heart device sales points to noticeable but not transformative effects on near-term results and sentiment.

8 Sep

3 www.marketbeat.com, 11:02 PM
Medtronic highlighted growth in AI, robotics and ablation at the Wells Fargo conference. Medtronic's push into AI, robotics and ablation targets strategic growth areas with moderate future upside.

3 , 8:58 AM
Medtronic shows improving growth but faces elevated risks, prompting questions on its buy worthiness. Improving growth at Medtronic is tempered by persistent elevated risks affecting its market performance.

3 transcript www.fool.com, 7:44 AM
Medtronic PLC held Q1 2027 earnings call covering financial results, operational updates and business outlook. Quarterly earnings call delivers updates on results and guidance that moderately shape near-term sentiment and valuation.

4 Sep

3 , 10:27 AM
Boston Scientific's ICVT business shows rising momentum, prompting questions on whether the growth trajectory can be sustained. Competitor momentum in cardiovascular devices creates moderate pressure on Medtronic's market position and growth outlook.

2 Sep

4 , 11:25 AM
Medtronic begins fiscal 2027 by beating expectations and raising guidance, which RBC states validates the company's growth acceleration. Beat-and-raise report with RBC validation signals significant positive shift in Medtronic growth trajectory and investor sentiment.

4 , 10:00 AM
Medtronic PLC posted broad Q1 growth across segments and raised full-year guidance. Raised guidance after broad growth signals major positive shift in financial outlook and investor sentiment.

4 www.medicaldevice-network.com, 7:04 AM
Medtronic raised its FY27 outlook after reporting strong Q1 growth. Raised FY27 outlook after strong Q1 growth signals improved financial trajectory and investor sentiment for Medtronic.

4 www.medtechdive.com, 5:00 AM
Medtronic PLC invests $700 million in Cornerstone Robotics to expand surgical robotics capabilities. $700 million investment marks major strategic push into high-growth surgical robotics sector.

1 Sep

4 transcript , 3:00 PM
Medtronic reported strong Q1 2027 revenue growth and raised guidance during its earnings call. Strong revenue growth and raised guidance point to major positive shifts in financial trajectory and investor outlook.

3 app.moby.co, 4:55 PM
Medtronic plc reported Q1 2027 earnings results including revenue, earnings per share, and segment performance along with management commentary on outlook and operations. Quarterly earnings data and guidance directly inform near-term financial expectations and stock valuation.

3 , 12:28 PM
Medtronic PLC nears a potential stock breakout while its spinoff MiniMed reaches a record high. MiniMed record high signals positive momentum that may lift Medtronic near-term sentiment without altering core operations.

3 transcript www.marketbeat.com, 11:02 AM
Medtronic's MiniMed Group released Q1 earnings call highlights covering financial results, operational updates and outlook. Quarterly earnings details can shift near-term sentiment and valuation for Medtronic without altering long-term strategy.

3 , 10:14 AM
Medtronic diabetes spinoff shares surged. Attention now centers on earnings metrics that could shape the new entity's standalone performance and investor view. Diabetes spinoff separation represents strategic shift with noticeable but not transformative effects on Medtronic operations and valuation.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us